CABA Cabaletta Bio, Inc.
P/E
--
Forward P/E
--
Price/Sales
--
Beta
3.475
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Cabaletta Bio second quarter 2026 results highlight mid-2027 clinical data and 2H27 BLA submission
Cabaletta Bio reported a second quarter 2026 net loss of $51.0 million, or $0.34 per share, as it continues to advance its late-stage clinical pipeline. The...
Cabaletta Bio Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
For the Q2 2026 reporting period, analysts expect Cabaletta Bio to post a loss of $0.37 per share on zero revenue, while the stock currently trades near $2.67...